ABSTRACT
INTRODUCTION

62
Visceral leishmaniasis (VL), a vector-borne disease is caused by intra-macrophage 63 trypanosomatid protozoa of the genus Leishmania (1,2) and is manifested by hematological and 64 hepatosplenic abnormalities with defective T-cell-dependant immune responses and is usually 65 fatal if not treated properly (3,4). Human VL causes an estimated 50,000 deaths annually, a rate 66 surpassed among parasitic diseases only by malaria, and 2,357,000 disability-adjusted life years 67 lost, placing leishmaniasis ninth position in a global analysis of infectious diseases (5). 68
Despite the availability of several chemotherapeutic drugs, successful management of VL 69
has not yet been attained. Indeed, amphotericin B (AmB) is used as a prototype leishmanicidal 70 drug due to its excellent efficacy with commercially great success. It possesses selective killing 71 activity against Leishmania mediated through its higher binding affinity for predominant substituted sterols (ergosterol and episterol) in the plasma membrane of parasite as these sterols 73
are not found in mammalian cells (6). However, toxic side effects, in particular hematological 74 intolerance and nephrotoxicity produced by AmB at therapeutic doses have often limited its 75 clinical application (7). 76
In the past few years, the capability of the drug delivery systems have been critically 77 tested to enhance the accessibility of the drug to reticuloendothelial system (RES) organs (liver 78 and spleen), ensuring delivery of less amount to the kidney and lungs, thus able to decrease AmB 79 mediated toxicity (8,9). The investigations for such newer less toxic formulations of AmB have 80 led to the development of commercial preparations for therapeutic use such as liposomal 81
AmBisome®, Abelcet® a AmB-lipid complex, and micellar Amphotec® (10,11 Fabrication of chitosan nanocapsule from the nano-emulsion template. Polymeric chitosan 137 nanocapsule (CNC) was generated with preformed chitosan polymer in two steps. Firstly, oil-in-138
water (o/w) nano-emulsion-template (NET) was formulated through modified spontaneous 139 emulsification solvent evaporation (25). Probe sonicator (SONICS, USA) was used to supply 140 high energy to prepare formulation, however prior to sonication the oil phase and the water phase 141 were prepared separately. Briefly, the organic phase consisted of absolute ethanol, 10% (w/w) 142 soyabean oil, 3% (w/w) nonionic lipophilic emulsifier (soya lecithin) was dispersed by means of 143 a magnetic stirrer until complete dissolution of SL was obtained. The aqueous phase composed 144 of 4% (w/w) hydrophilic emulsifier (Tween 80), 2.25% (w/w) osmotic agent (glycerol) and 145 water, was obtained by dissolving the stabilizer in the water. Finally AmB solution in acidic 146 methanol was added in the oil phase. The NET was obtained by adding the oil phase to the 147 aqueous phase both being adjusted to the same temperature. Afterwards sonifier high energy was 148 supplied at 40% amplitude for 4 min and the excess of solvents mixture (ethanol/water) was 149 subsequently removed under reduced pressure at 50 o C until the desired final volume (10 ml). 150 Secondly, CNC nanocarrier was generated by coating droplets of NET with the chitosan 151 deposition on the water/oil surface (26). In order to prepare CNC-AmB, the chitosan solution 152 using 1% (v/v) glacial acetic acid with varying compositions (0.1, 0.2, 0.4, 0.6, 0.8 and 1% w/v 153 coded by NC-1, NC-2, NC-4, NC-6, NC-8 and NC-10, respectively) and ethanol in equimolar 154 ratio was gradually added in the continuous aqueous phase of the NET in 1:10 ratio and was 155 stirred uncovered at room temperature for complete evaporation of ethanol (IKA, Germany). The 156 polymer precipitated onto the droplets, forming chitosan-coated oil nanodroplets (CNC). This 157 CNC dispersion was sterilized by filtration through a disposable syringe filter (0.45 μm Millipore 158 filter) with not more than 5 ml of dispersion was filtered through each disposable syringe filter. 159 index (PDI) of prepared nanocarriers were determined using a photon correlation spectroscopy 165 (PCS) and the zeta potential was determined using electrophoretic mobility with laser-based 166 multiple-angle particle electrophoresis analyzer at 25 o C (Zetasizer Nano-ZS, Malvern 167
Instruments, Worcestershire, UK) just after dispersion in deionized water. All of the 168 measurements were performed in triplicates. 169
The morphologic characteristic was ascertained using high resolution transmission 170 electron microscopy (HR-TEM). For the HR-TEM measurement, samples (1mg/20 ml) were 171 prepared as a thin aqueous film supported on a 300-mesh copper grid. Negative staining was 172 performed using a droplet of 2% (w/v) phosphotungstic acid. Direct imaging of dried samples 173 was executed at a 200 kV acceleration voltage using HR-TEM (Tecnai™ G 2 F20, Eindhoven, 174
The Netharlands). 
RESULTS
279
Fabrication and characterization of nanocapsules. CNC were produced by applying polymer 280 deposition and adsorption approach where chitosan was allowed to become electrostatically 281 anchored and deposited on negatively charged water/oil surface of NET droplets that was 282 produced by application of ultrasound energy using sonifiers employing Tween 80 and SL as 283 surfactants, and soyabean oil as the central oily core. The excipients which we have used in 284 formulation are generally considered safe for use in parenteral formulations. The combination of 285 surfactants with oils to form NET offers an advantage over commercial micellar or co-solvent 286 system in terms of drug solubilization capacities for amphiphilic compounds (33). Chitosan 287 concentration was optimized by measuring the change in zeta potential, size and stability of 288 nanocapsule dispersions. The CNC prepared using 0.6% w/v chitosan (NC-6) had the electric 289 on July 9, 2017 by guest http://aac.asm.org/ Downloaded from charge of (+) 29±0.82 mV with 145.8±8.91 nm size (n=3) and observed as the most stable 290 formulation, while NC-4 (0.4% w/v chitosan) showed aggregation characteristics while NC-8 291 exhibited larger size (Fig. S2) and therefore, 0.6% w/v chitosan concentration was selected for 292 optimized CNC. The characteristics of the optimized formulations (NET and CNC i.e., NC-6 293 using 0.6% chitosan) are showed in Table S1 . The mean size (PDI) of the NET and CNC was 294 around 101.4±7.08 nm (0.105±0.03) and 145.8±8.91 nm (0.122±0.04), respectively (n=3) as 295 determined by PCS. HRTEM explorations of the optimized delivery system confirmed the nano 296 sizes of the carriers (100-150 nm). The important relevant results from the TEM study (Fig. S3 ) 297
illustrates that the prepared CNC has spherical morphology and development of CNC is signified 298 by the continuous chitosan shielding layer of about 16 nm thickness over plain NET droplets. 299
Developed formulations were found to be highly efficient for AmB entrapment (Table S1) . Ambisome and Fungizone showed hemotoxicity upto 6.321±1.02 and 100% respectively (Table  314 1). All tested formulations composed of AmB concentration in the range of 0.25-25µg/ml. 315
In vitro uptake studies. efficacy of CNC-AmB was supported by a surge in iNOS, TNF-α and IL-12 mRNA levels. The 338 levels of Th-2 cytokines IL-4, IL-10 and TGF-β mRNA, on the other hand, were observed to be 339 down-regulated in the treated hamsters. Study showed significant differences between the treated 340 and control groups (Fig. 4) . 341
DISCUSSION
342
A variety of intracellular parasites including Leishmania can survive and multiply within cells of 343 the MPS particularly MPφ which serve as reservoir for them owing to the development of 344 potential ability to resist phagocytosis activity. Nanocarrier systems can be advantageous in 345 treating these types of infection because they themselves are concentrated within phagocyte cells 346 and provide direct contact of drug bearing carrier with parasites. 347
In the present study, we developed and evaluated a novel NE-template (NET) based 348 stable lipid formulation, the CNC-AmB, in treatment of L. donovani infection in vitro and in vivo 349 and its toxicity profile. Additionally, we investigated the changes on phagocytosis activity and 350 cytokine production of MPφ after stimulation by CNC-AmB. To assess the efficacy of CNC-351 AmB, we compared its study results with that of NET-AmB and, commercial Fungizone and 352
Ambisome. to NET may be partially due to a longer exposure of NET droplets to the solvent during the 376 modification process, leading to a loss of the drug (Table S1 ). Fig. S4 showed that release ratio 377 of drug from NET-AmB significantly exceeded with the CNC in 24 h, which indicated 378 restriction of drug release due to chitosan surface layer. Thereafter, release from CNC-AmB 379 increased comparatively because of the hydrophilic chitosan which allows greater ease for the 380 release medium to penetrate, facilitating release of AmB from the swelled CNC. However, it has 381 been reported that the incorporation of AmB to fat emulsions resulted in precipitation of AmB 382 (41), whereas in the developed CNC it is highly stable. 383
Because nanocarrier stability is greatly influenced by surface charge (zeta potential), as 384 shown in 
